The Silicon Review has identified iCHOR Vascular as on of the fastest growing innovative companies on its radar to watch in 2026. The article summarizes iCHOR’s mission as follows:
“Today, iCHOR Vascular is positioning itself as a transformative force in peripheral vascular intervention by developing simple, versatile, and predictable technologies designed specifically for vascular surgeons and interventional radiologists seeking better patient outcomes with fewer procedural burdens. The company’s approach addresses a major unmet need in vascular care, where patients suffering from dangerous peripheral blood clots are often forced to choose between invasive surgery with ICU recovery or clot-dissolving drugs that increase bleeding risk and prolong hospital stays.
By reimagining the surgical “wall-to-wall sweep” mechanism through an endovascular platform, iCHOR aims to create a first-line therapy that combines clinical reliability with operational efficiency. The company has already treated more than 100 patients through its limited market release, demonstrating growing clinical confidence in its technology and validating its real-world potential. For medical device investors, iCHOR represents an opportunity at the intersection of vascular innovation, procedural efficiency, and cost-conscious healthcare delivery. With a focused leadership team, strong clinical insight, and a mission rooted in solving longstanding industry challenges, iCHOR Vascular is steadily advancing toward redefining the future of peripheral vascular occlusion treatment.”
According to the article, Timothy Blair, iCHOR Vascular Inc. CEO, explains, “What drives me is simple: we’re saving lives, and we’re doing it with elegant simplicity. That’s a mission worth every ounce of effort.”
Read more articles: iCHOR in the News
